These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

988 related items for PubMed ID: 18578960

  • 1. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeverbeke T.
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [Abstract] [Full Text] [Related]

  • 2. Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept.
    Aghdashi MA, Khadir M, Dinparasti-Saleh R.
    Curr Rheumatol Rev; 2020; 16(1):61-66. PubMed ID: 31057111
    [Abstract] [Full Text] [Related]

  • 3. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 4. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM.
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [Abstract] [Full Text] [Related]

  • 5. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study.
    Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N.
    Arthritis Res Ther; 2004 Jan; 6(6):R535-43. PubMed ID: 15535831
    [Abstract] [Full Text] [Related]

  • 6. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, Zingarelli S, Caporali R, Cattaneo R, Montecucco CM.
    Clin Exp Rheumatol; 2007 Jan; 25(5):676-83. PubMed ID: 18078613
    [Abstract] [Full Text] [Related]

  • 7. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 8. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.
    Semin Arthritis Rheum; 2004 Feb; 33(4):283-8. PubMed ID: 14978666
    [Abstract] [Full Text] [Related]

  • 9. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 10. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E.
    Clin Exp Rheumatol; 2010 May; 28(5):661-8. PubMed ID: 20822711
    [Abstract] [Full Text] [Related]

  • 11. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [Abstract] [Full Text] [Related]

  • 12. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K, Lequerré T, Vittecoq O.
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [Abstract] [Full Text] [Related]

  • 13. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients.
    Bacquet-Deschryver H, Jouen F, Quillard M, Ménard JF, Goëb V, Lequerré T, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    J Clin Immunol; 2008 Sep; 28(5):445-55. PubMed ID: 18587633
    [Abstract] [Full Text] [Related]

  • 14. [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab].
    Hoxha A, Ruffatti A, Grypiotis P, Podswiadek M, Botsios C, Fiocco U, Punzi L, Todesco S.
    Reumatismo; 2006 Sep; 58(2):121-6. PubMed ID: 16829990
    [Abstract] [Full Text] [Related]

  • 15. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 16. [Anti-TNFalpha treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies].
    Cavazzana I, Franceschini F, Danieli E, Frassi M, Vianelli M, Gorla R, Airò P, Cattaneo R.
    Reumatismo; 2005 Dec; 57(4):267-72. PubMed ID: 16380754
    [Abstract] [Full Text] [Related]

  • 17. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 18. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH, Gutiérrez-Cívicos MR, García-Simón MS, Conesa-Zamora P, Jimenez-Santos E, Cano-Vivar P, García-Márquez A, Muñoz-García I, Viney AC.
    Ann Pharmacother; 2017 May 18; 51(5):388-393. PubMed ID: 27920336
    [Abstract] [Full Text] [Related]

  • 19. [TNF-alpha inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunologic effects].
    Cavazzana I, Bobbio-Pallavicini F, Bazzani C, Bravi E, Zingarelli S, Ceribelli A, Caporali R, Cattaneo R, Franceschini F, Montecucco C.
    Reumatismo; 2006 May 18; 58(4):275-82. PubMed ID: 17216016
    [Abstract] [Full Text] [Related]

  • 20. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.
    Schulz M, Dotzlaw H, Neeck G.
    Biomed Res Int; 2014 May 18; 2014():675108. PubMed ID: 24783218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.